KR20220151637A - Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합 - Google Patents

Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합 Download PDF

Info

Publication number
KR20220151637A
KR20220151637A KR1020227034176A KR20227034176A KR20220151637A KR 20220151637 A KR20220151637 A KR 20220151637A KR 1020227034176 A KR1020227034176 A KR 1020227034176A KR 20227034176 A KR20227034176 A KR 20227034176A KR 20220151637 A KR20220151637 A KR 20220151637A
Authority
KR
South Korea
Prior art keywords
weeks
administered
lsd
inhibitor
nivolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227034176A
Other languages
English (en)
Korean (ko)
Inventor
엘렌 필바로프
이다 아론치크
트레이시 초우
에릭 올슨
브라이언 폭스
마리아 왕
Original Assignee
셀젠 콴티셀 리서치, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀젠 콴티셀 리서치, 인크. filed Critical 셀젠 콴티셀 리서치, 인크.
Publication of KR20220151637A publication Critical patent/KR20220151637A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227034176A 2020-03-06 2021-03-05 Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합 Ceased KR20220151637A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986541P 2020-03-06 2020-03-06
US62/986,541 2020-03-06
PCT/US2021/021101 WO2021178807A1 (en) 2020-03-06 2021-03-05 Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc

Publications (1)

Publication Number Publication Date
KR20220151637A true KR20220151637A (ko) 2022-11-15

Family

ID=77614361

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034176A Ceased KR20220151637A (ko) 2020-03-06 2021-03-05 Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합

Country Status (11)

Country Link
US (1) US20230089536A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114398A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023516745A (cg-RX-API-DMAC7.html)
KR (1) KR20220151637A (cg-RX-API-DMAC7.html)
CN (1) CN115484958A (cg-RX-API-DMAC7.html)
AU (1) AU2021230575A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017637A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170456A1 (cg-RX-API-DMAC7.html)
IL (1) IL296564A (cg-RX-API-DMAC7.html)
MX (1) MX2022010912A (cg-RX-API-DMAC7.html)
WO (1) WO2021178807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
TW202329934A (zh) * 2021-09-30 2023-08-01 日商大鵬藥品工業股份有限公司 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) * 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
CA3143030A1 (en) * 2019-06-13 2020-12-17 Celgene Corporation Methods of treating cancer by targeting cold tumors

Also Published As

Publication number Publication date
MX2022010912A (es) 2022-11-09
EP4114398A1 (en) 2023-01-11
CN115484958A (zh) 2022-12-16
JP2023516745A (ja) 2023-04-20
BR112022017637A2 (pt) 2022-11-08
US20230089536A1 (en) 2023-03-23
CA3170456A1 (en) 2021-09-10
WO2021178807A1 (en) 2021-09-10
IL296564A (en) 2022-11-01
AU2021230575A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
JP7653398B2 (ja) 癌を処置するためのグルタミン酸調節剤と免疫療法の併用
US12528865B2 (en) Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
JP2024170447A (ja) Pd-1/pd-l1シグナル伝達を破壊することによる癌免疫療法
TW202123967A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2017522261A (ja) Ceacam1に対するヒト化抗体
JP2019517505A (ja) リンパ腫処置における抗cd30抗体と組み合わせた抗pd−1抗体の使用
JP2019517504A (ja) 難治性ホジキンリンパ腫におけるニボルマブでのpd−1遮断
WO2021178807A1 (en) Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
JP2022527334A (ja) 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法
KR20220137007A (ko) Pd-1 길항제, ilt4 길항제 및 렌바티닙 또는 그의 염을 사용하는 조합 암 치료
JP2023551980A (ja) 抗体およびタキソンの併用療法
CN113677402A (zh) 治疗肿瘤的方法
JP2024511977A (ja) 抗ilt3抗体によるがんの治療方法
TW202535462A (zh) 在ctdna高風險患者中的抗cd20/抗cd3雙特異性抗體與化學療法之組合治療
JP7817242B2 (ja) 鼻咽頭癌の治療における抗pd-1抗体の使用
JP2021523879A (ja) 後期肺癌の処置のための組成物及び方法
JP2024144605A (ja) がんを処置するための方法および組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601